Turkiye Klinikleri Journal of Dermatology

.: REVIEW
Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme
N-Acetylcysteine Uses in Dermatology Traditional Compilation: Traditional Review
Göknur KALKANa
aAnkara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi, Deri ve Zührevi Hastalıkları ABD, Ankara, Türkiye
Turkiye Klinikleri J Dermatol. 2022;32(2):120-7
doi: 10.5336/dermato.2021-86988
Article Language: TR
Full Text
ÖZET
 Mukolitik ve nefroprotektif bir ajan olan N-asetilsistein, yaygın olarak asetaminofen toksisitesinde antidot olarak kullanılır. Bir sistein donörü olarak hareket ederek, antioksidan, antiinflamatuar ve antiproliferatif etkileri oluşturur. Nörotransmitter düzeylerinde de değişikliğe yol açar. Fibroblastların ve keratinositlerin çoğalmasını engeller, vazodilatasyona neden olur. Bu özellikleriyle nöroloji, psikiyatri, nefroloji, maligniteler, çeşitli vasküler bozukluklar ve akciğer hastalıklarına kadar çok çeşitli tıbbi alanlarda potansiyel kullanım alanı bulmuştur. Dermatoloji alanındaki kullanımları, sistemik ve topikal formda olmak üzere küçük çaplı çalışmalar ve olgu sunumları, vaka serileri şeklinde literatürde bildirilmiştir. Burada sırasıyla ilaç reaksiyonları (toksik epidermal nekroliz ve ilaç hipersensitivite sendromu); trikotillomani, trikoteiromani, onikotillomani gibi deri yolma bozukluklarını içeren psikodermatozlar; iktiyozlar, kontakt dermatit ve atopik dermatit gibi epidermal bariyer/keratinizasyon bozuklukları olan hastalıklar; kseroderma pigmentozum, melazma, psödoporfiri gibi fotodermatozlar; sistemik skleroz ve lupus eritematozus gibi konnektif doku hastalıkları; yara iyileşmesi ve büllöz morfea; polikistik over sendromu, hiperandrojenizm, akne ve alopesideki kullanım alanlarına değinilecektir. Her ne kadar ilacın temini kolay ve güvenlik profili iyi olsa da daha geniş çapta kullanım için kanıt düzeyinin daha yüksek olması gerekli görülmektedir. Bu derlemede, N-asetilsisteinin dermatoloji alanındaki mevcut çeşitli kullanım alanları ve etki mekanizmaları gözden geçirilerek, günlük dermatoloji pratiğinde göz ardı edilen potansiyel kullanım alanlarına dikkat çekilmesi hedeflenmiştir. Dermatolojik hastalıklar için güvenli ve umut veren bir seçenek olabileceği düşünülmektedir.

Anahtar Kelimeler: N-asetilsistein; antioksidan; antiinflamatuar; nörotransmitter
ABSTRACT
 N-acetylcysteine, a mucolytic and nephroprotective agent, is frequently used as an antidote to acetaminophen toxicity. Acting as a cysteine donor, it has antioxidant, anti-inflammatory and antiproliferative effects. It also causes changes in neurotransmitter levels. It prevents the proliferation of fibroblasts and keratinocytes, generates vasodilation. With these properties, it has found potential use in a wide variety of medical fields, from neurology, psychiatry, nephrology, malignancies, various vascular disorders to lung diseases. Their use in dermatology has been reported in the literature in the form of small-scale studies, case reports, case series, in systemic and topical forms. Here, respectively; the usage areas in drug reactions (toxic epidermal necrolysis and drug hypersensitivity syndrome); psychodermatoses including skin picking disorders such as trichotillomania, trichotillomania, onychotillomania; diseases with epidermal barrier/keratinization disorders such as ichthyoses, contact dermatitis and atopic dermatitis; photodermatoses such as xeroderma pigmentosum, melasma, pseudoporphyria; connective tissue diseases such as systemic sclerosis and lupus erythematosus; wound healing and bullous morphea; polycystic ovary syndrome, hyperandrogenism, acne and alopecia will be mentioned. Although the drug is easy to obtain and has a good safety profile, a higher level of evidence is required for wider use. In this review, the current usage areas and mechanisms of action of N-acetylcysteine in dermatology are reviewed and it is aimed to draw attention to the potential usage areas that are overlooked in daily dermatology practice. It is considered to be a safe and promising option for dermatological diseases.

Keywords: N-acetylcysteine; antioxidant; anti-inflammatory; neurotransmitter
REFERENCES:
  1. Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265-9. [PubMed] 
  2. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117-29. [Crossref]  [PubMed] 
  3. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4(2):108-22. [Crossref]  [PubMed]  [PMC] 
  4. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20(2):123-34. [Crossref]  [PubMed] 
  5. Kerksick C, Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J Int Soc Sports Nutr. 2005;2(2):38-44. [Crossref]  [PubMed]  [PMC] 
  6. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355-9. [Crossref]  [PubMed]  [PMC] 
  7. Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int. 2010;30(3):336-42. [Crossref]  [PubMed] 
  8. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25(27):6389-93. [Crossref]  [PubMed]  [PMC] 
  9. Gere-Pászti E, Jakus J. The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr. 2009;23(6):658-64. [Crossref]  [PubMed] 
  10. Sekharam M, Trotti A, Cunnick JM, Wu J. Suppression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998;149(2):210-6. [Crossref]  [PubMed] 
  11. Allegra L, Dal Sasso M, Bovio C, Massoni C, Fonti E, Braga PC. Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneimittelforschung. 2002;52(9):669-76. [Crossref]  [PubMed] 
  12. Redondo P, Ruiz de Erenchun F, Iglesias ME, Monedero P, Quintanilla E. Toxic epidermal necrolysis. Treatment with pentoxifylline. Br J Dermatol. 1994;130(5):688-9. [Crossref]  [PubMed] 
  13. Vélez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol. 2002;46(3):469-70. [Crossref]  [PubMed] 
  14. Saavedra C, Cárdenas P, Castellanos H, Contreras K, Castro JR. Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine. Case Reports Immunol. 2012;2012:931528. [Crossref]  [PubMed]  [PMC] 
  15. Yavuz H, Emiroglu M. Toxic epidermal necrolysis treated with N-acetylcysteine. Pediatr Int. 2014;56(5):e52-4. [Crossref]  [PubMed] 
  16. Moling O, Tappeiner L, Piccin A, Pagani E, Rossi P, Rimenti G, et al. Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis. Med Sci Monit. 2012;18(7):CS57-62. [Crossref]  [PubMed]  [PMC] 
  17. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6-11. [Crossref]  [PubMed] 
  18. Jose J, Klein R. Successful treatment of sulfasalazine-induced DRESS syndrome with corticosteroids and N-acetylcysteine. Pharmacotherapy. 2011;31:1043. [Crossref] 
  19. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756-63. [Crossref]  [PubMed] 
  20. Rodrigues-Barata AR, Tosti A, Rodríguez-Pichardo A, Camacho-Martínez F. N-acetylcysteine in the Treatment of Trichotillomania. Int J Trichology. 2012;4(3):176-8. [Crossref]  [PubMed]  [PMC] 
  21. Taylor M, Bhagwandas K. N-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders? Br J Dermatol. 2014;171(5):1253-5. [Crossref]  [PubMed] 
  22. Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013;52(3):231-40. [PubMed]  [PMC] 
  23. Salas-Callo CI, Pirmez R. Trichoteiromania: good response to treatment with n-acetylcysteine. Skin Appendage Disord. 2019;5(4):242-5. [Crossref]  [PubMed]  [PMC] 
  24. Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014;164A(2):421-4. [Crossref]  [PubMed] 
  25. Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490-6. [Crossref]  [PubMed] 
  26. Taylor M, Bhagwandas K. Trichotillosis, skin picking and N-acetylcysteine. J Am Acad Dermatol. 2015;72 Suppl 1:AB117. [Crossref] 
  27. Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem. 2013;12(3):223-8. [Crossref]  [PubMed] 
  28. Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr. 2009;14(7):357-60. [Crossref]  [PubMed] 
  29. Redondo P, Bauzá A. Topical N-acetylcysteine for lamellar ichthyosis. Lancet. 1999;354(9193):1880. [Crossref]  [PubMed] 
  30. Sarici SU, Sahin M, Yurdakök M. Topical N-acetylcysteine treatment in neonatal ichthyosis. Turk J Pediatr. 2003;45(3):245-7. [PubMed] 
  31. Bassotti A, Moreno S, Criado E. Successful treatment with topical N-acetylcysteine in urea in five children with congenital lamellar ichthyosis. Pediatr Dermatol. 2011;28(4):451-5. [Crossref]  [PubMed] 
  32. Deffenbacher B. Successful experimental treatment of congenital ichthyosis in an infant. BMJ Case Rep. 2013;2013:bcr2013008688. [Crossref]  [PubMed]  [PMC] 
  33. Nakai K, Yoneda K, Hosokawa Y, Moriue T, Presland RB, Fallon PG, et al. Reduced expression of epidermal growth factor receptor, E-cadherin, and occludin in the skin of flaky tail mice is due to filaggrin and loricrin deficiencies. Am J Pathol. 2012;181(3):969-77. [Crossref]  [PubMed] 
  34. Nakai K, Yoneda K, Murakami Y, Koura A, Maeda R, Tamai A, et al. Effects of topical N-acetylcysteine on skin hydration/transepidermal water loss in healthy volunteers and atopic dermatitis patients. Ann Dermatol. 2015;27(4):450-1. [Crossref]  [PubMed]  [PMC] 
  35. Senaldi G, Pointaire P, Piguet PF, Grau GE. Protective effect of N-acetylcysteine in hapten-induced irritant and contact hypersensitivity reactions. J Invest Dermatol. 1994;102(6):934-7. [Crossref]  [PubMed] 
  36. Pasche-Koo F, Arechalde A, Arrighi JF, Hauser C. Effect of N-acetylcysteine, an inhibitor of tumor necrosis factor, on irritant contact dermatitis in the human. Curr Probl Dermatol. 1995;23:198-206. [Crossref]  [PubMed] 
  37. Kang S, Chung JH, Lee JH, Fisher GJ, Wan YS, Duell EA, et al. Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. J Invest Dermatol. 2003;120(5):835-41. [Crossref]  [PubMed] 
  38. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res. 2007;13(19):5952-8. [Crossref]  [PubMed]  [PMC] 
  39. Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, et al. Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res. 2009;15(23):7434-40. [Crossref]  [PubMed]  [PMC] 
  40. Redondo P, Bandrés E, Solano T, Okroujnov I, García-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine. 2000;12(4):374-8. [Crossref]  [PubMed] 
  41. Margaryan NV, Gilgur A, Seftor EA, Purnell C, Arva NC, Gosain AK, et al. Melanocytes affect nodal expression and signaling in melanoma cells: a lesson from pediatric large congenital melanocytic nevi. Int J Mol Sci. 2016;17(3):418. [Crossref]  [PubMed]  [PMC] 
  42. Kunisada M, Hosaka C, Takemori C, Nakano E, Nishigori C. CXCL1 inhibition regulates UVB-induced skin inflammation and tumorigenesis in Xpa-deficient mice. J Invest Dermatol. 2017;137(9):1975-83. [Crossref]  [PubMed] 
  43. Reliene R, Fischer E, Schiestl RH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004;64(15):5148-53. [Crossref]  [PubMed] 
  44. Demirel C, Kilciksiz S, Evirgen-Ayhan S, Gurgul S, Erdal N. The preventive effect of N-acetylcysteine on radiation-induced dermatitis in a rat model. J BUON. 2010;15(3):577-82. [PubMed] 
  45. Kim JA, Baker DG, Hahn SS, Goodchild NT, Constable WC. Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. Semin Oncol. 1983;10(1 Suppl 1):86-92. [PubMed] 
  46. Sehgal VN, Verma P, Srivastava G, Aggarwal AK, Verma S. Melasma: treatment strategy. J Cosmet Laser Ther. 2011;13(6):265-79. [Crossref]  [PubMed] 
  47. Njoo MD, Menke HE, Pavel W, Westerhof W. N-acetylcysteine as a bleaching agent in the treatment of melasma. J Eur Acad Dermatol Venereol. 1997;9:86-7. [Crossref] 
  48. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol. 2000;142(3):580-1. [Crossref]  [PubMed] 
  49. Cooke NS, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol. 2007;32(1):64-6. [PubMed] 
  50. Velioglu A, Ergun T, Ozener C. Pseudoporphyria in a peritoneal dialysis patient. Perit Dial Int. 2015;35(2):234-5. [Crossref]  [PubMed]  [PMC] 
  51. Katoulis AC, Ferra D, Toumbis E, Papadavid E, Kanelleas A, Panayiotides I, et al. Pseudoporphyria associated with nonhemodialyzed renal insufficiency, successfully treated with oral N-acetylcysteine. Case Rep Dermatol Med. 2013;2013:271873. [Crossref]  [PubMed]  [PMC] 
  52. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38(4):356-61. [Crossref]  [PubMed]  [PMC] 
  53. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study. J Rheumatol 2001;28:2257-62.
  54. Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009;28(12):1379-84. [Crossref]  [PubMed] 
  55. Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double blind, placebo controlled trial. Arthritis Rheum 2012;64:2937 46. [Crossref]  [PubMed]  [PMC] 
  56. Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Panomvana Na Ayudhya D. The effect of high dose of N acetylcysteine in lupus nephritis: A case report and literature review. J Clin Pharm Ther 2010;35:483 5. [Crossref]  [PubMed] 
  57. Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:1313 8. [Crossref]  [PubMed]  [PMC] 
  58. Ozkaya H, Bahat G, Tufan A, Dogan H, Bilicen Z, Karan MA. Successful treatment of non-healing pressure ulcers with topical n-acetyl cysteine. J Wound Care. 2015;24(12):606, 608-11. [Crossref]  [PubMed] 
  59. Deniz M, Borman H, Seyhan T, Haberal M. An effective antioxidant drug on prevention of the necrosis of zone of stasis: N-acetylcysteine. Burns. 2013;39(2):320-5. [Crossref]  [PubMed] 
  60. Demir EO, Cakmak GK, Bakkal H, Turkcu UO, Kandemir N, Demir AS, et al. N-acetyl-cysteine improves anastomotic wound healing after radiotherapy in rats. J Invest Surg. 2011;24(4):151-8. [Crossref]  [PubMed] 
  61. Aktunc E, Ozacmak VH, Ozacmak HS, Barut F, Buyukates M, Kandemir O, et al. N-acetyl cysteine promotes angiogenesis and clearance of free oxygen radicals, thus improving wound healing in an alloxan-induced diabetic mouse model of incisional wound. Clin Exp Dermatol. 2010;35(8):902-9. [Crossref]  [PubMed] 
  62. Rosato E, Veneziano ML, Di Mario A, Molinaro I, Pisarri S, Salsano F. Ulcers caused by bullous morphea: successful therapy with N-acetylcysteine and topical wound care. Int J Immunopathol Pharmacol. 2013;26(1):259-62. [Crossref]  [PubMed] 
  63. Oner G, Muderris II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):127-31. [PubMed] 
  64. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. 2015;2015:817849. [Crossref]  [PubMed]  [PMC] 
  65. Sahib AS, Al-Anbari HH, Salih M, Abdullah F. Effect of oral antioxidants on lesion counts associated with oxidative stress and inflammation in patients with papulopustular acne. J Clin Exp Dermatol Res. 2012;3(5):163. [Crossref] 
  66. Montes LF, Wilborn WH, Montes CM. Topical acne treatment with acetylcysteine: clinical and experimental effects. Skinmed. 2012;10(6):348-51. [PubMed] 
  67. Eroshenko D, Polyudova T, Korobov V. N-acetylcysteine inhibits growth, adhesion and biofilm formation of Gram-positive skin pathogens. Microb Pathog. 2017;105:145-52. [Crossref]  [PubMed] 
  68. Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative stress-associated senescence in dermal papilla cells of men with androgenetic alopecia. J Invest Dermatol. 2015;135(5):1244-52. [Crossref]  [PubMed] 
  69. D'Agostini F, Bagnasco M, Giunciuglio D, Albini A, De Flora S. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol. 1998;13(2):217-24. [Crossref]  [PubMed] 
  70. Li J, Xu L, Deng X, Jiang C, Pan C, Chen L, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016;157(8):1711-23. [Crossref]  [PubMed] 
  71. Kamboj SS, Vasishta RK, Sandhir R. N-acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. J Neurochem. 2010;112(1):77-91. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com